Clinical perspectives on pulmonary systemic and macromolecular delivery
- PMID: 16996638
- DOI: 10.1016/j.addr.2006.07.009
Clinical perspectives on pulmonary systemic and macromolecular delivery
Abstract
The large epithelial surface area, the high organ vascularization, the thin nature of the alveolar epithelium and the immense capacity for solute exchange are factors that led the lung to serve as an ideal administration route for the application of drugs for treatment of systemic disorders. However, the deposition behaviour of aerosol particles in the respiratory tract depends on a number of physical (e.g. properties of the particle), chemical (e.g. properties of the drug) and physiological (e.g. breathing pattern, pulmonary diseases) factors. If these are not considered, it will not be possible to deposit a reproducible and sufficient amount of drug in a predefined lung region by means of aerosol inhalation. The lack of consideration of such issues led to many problems in inhalation drug therapy for many years mainly because physiological background of aerosol inhalation was not fully understood. However, over the last 20 years, there has been considerable progress in aerosol research and in the understanding of the underlying mechanisms of particle inhalation and pulmonary particle deposition. As a consequence, an increasing number of studies have been performed for the lung administration of drugs using a variety of different inhalation techniques. This review describes the physical and in part some of the physiological requirements that need to be considered for the optimization of pulmonary drug delivery to target certain lung regions.
Similar articles
-
Novel approaches to enhance pulmonary delivery of proteins and peptides.J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):615-25. J Physiol Pharmacol. 2007. PMID: 18204175 Review.
-
Systemic treatment by inhalation of macromolecules--principles, problems, and examples.J Physiol Pharmacol. 2008 Dec;59 Suppl 6:53-79. J Physiol Pharmacol. 2008. PMID: 19218633 Review.
-
Treatment of systemic diseases by inhalation of biomolecule aerosols.J Physiol Pharmacol. 2009 Nov;60 Suppl 5:15-26. J Physiol Pharmacol. 2009. PMID: 20134033 Review.
-
Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology.J Microencapsul. 2009 Feb;26(1):1-8. doi: 10.1080/02652040802083900. J Microencapsul. 2009. PMID: 18465287
-
Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action.Nutrition. 2010 Jan;26(1):33-9. doi: 10.1016/j.nut.2009.08.001. Nutrition. 2010. PMID: 20005465 Review.
Cited by
-
Preparation, Statistical Optimization and In-vitro Characterization of a Dry Powder Inhaler (DPI) Containing Solid Lipid Nanoparticles Encapsulating Amphotericin B: Ion Paired Complexes with Distearoyl Phosphatidylglycerol.Iran J Pharm Res. 2020 Summer;19(3):45-62. doi: 10.22037/ijpr.2019.15208.12963. Iran J Pharm Res. 2020. PMID: 33680009 Free PMC article.
-
Optimizing the Entrainment Geometry of a Dry Powder Inhaler: Methodology and Preliminary Results.Pharm Res. 2016 Nov;33(11):2668-79. doi: 10.1007/s11095-016-1992-3. Epub 2016 Jul 11. Pharm Res. 2016. PMID: 27401410 Free PMC article.
-
Agile delivery of protein therapeutics to CNS.J Control Release. 2014 Sep 28;190:637-63. doi: 10.1016/j.jconrel.2014.06.017. Epub 2014 Jun 21. J Control Release. 2014. PMID: 24956489 Free PMC article. Review.
-
Experimental research on surface acoustic wave microfluidic atomization for drug delivery.Sci Rep. 2022 May 13;12(1):7930. doi: 10.1038/s41598-022-11132-9. Sci Rep. 2022. PMID: 35562384 Free PMC article.
-
Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms.Drug Deliv Transl Res. 2021 Aug;11(4):1752-1765. doi: 10.1007/s13346-021-01002-8. Epub 2021 May 28. Drug Deliv Transl Res. 2021. PMID: 34047967 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials